GAMMA Investing LLC Boosts Holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

GAMMA Investing LLC grew its holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 1,155.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 39,010 shares of the biotechnology company's stock after buying an additional 35,902 shares during the quarter. GAMMA Investing LLC's holdings in Aurinia Pharmaceuticals were worth $314,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Invesco Ltd. lifted its stake in Aurinia Pharmaceuticals by 1.0% in the fourth quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock worth $1,294,000 after acquiring an additional 1,421 shares during the period. Bridgefront Capital LLC raised its holdings in Aurinia Pharmaceuticals by 12.9% in the 4th quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company's stock worth $149,000 after purchasing an additional 1,891 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of Aurinia Pharmaceuticals by 3.2% in the 4th quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company's stock worth $580,000 after purchasing an additional 2,000 shares during the period. Teacher Retirement System of Texas boosted its stake in shares of Aurinia Pharmaceuticals by 5.9% during the 4th quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company's stock valued at $324,000 after purchasing an additional 2,020 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after buying an additional 2,635 shares during the period. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Stock Up 2.8%

AUPH traded up $0.22 during trading on Tuesday, reaching $8.05. The stock had a trading volume of 1,409,823 shares, compared to its average volume of 1,327,735. The company has a current ratio of 5.93, a quick ratio of 5.26 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of 28.75 and a beta of 1.15. The stock's 50 day moving average is $8.04 and its two-hundred day moving average is $8.19. Aurinia Pharmaceuticals Inc has a one year low of $5.20 and a one year high of $10.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. Aurinia Pharmaceuticals had a net margin of 16.11% and a return on equity of 14.27%. The company had revenue of $62.47 million during the quarter, compared to analysts' expectations of $61.06 million. As a group, analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.